Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 04, 2014 07:00 ET | Source: Curis, Inc.

Curis to Present at the 26th Annual ROTH Conference

LEXINGTON, Mass., March 4, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today...
February 25, 2014 07:00 ET | Source: Curis, Inc.

Curis to Present at the Cowen and Company 34th Annual Health Care Conference

LEXINGTON, Mass., Feb. 25, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today...
February 20, 2014 07:00 ET | Source: Curis, Inc.

Curis Reports Fourth Quarter and Year-End 2013 Financial Results

LEXINGTON, Mass., Feb. 20, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today reported...
February 19, 2014 16:15 ET | Source: Curis, Inc.

Curis to Present at the RBC Capital Markets Global Healthcare Conference

LEXINGTON, Mass., Feb. 19, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human cancers,...
February 13, 2014 07:00 ET | Source: Curis, Inc.

Curis to Release Fourth Quarter and Year End 2013 Financial Results and Hold Conference Call on February 20, 2014

LEXINGTON, Mass., Feb. 13, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, today...
February 05, 2014 07:00 ET | Source: Curis, Inc.

Curis to Present at the Leerink Global Healthcare Conference

LEXINGTON, Mass., Feb. 5, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human cancers,...
December 09, 2013 11:00 ET | Source: Curis, Inc.

Curis Reports CUDC-907 Preliminary Data From the Ongoing Phase 1 Trial at ASH 2013 Annual Meeting

CUDC-907 (HDAC and PI3K inhibitor) demonstrates preliminary evidence of clinical activity Dose escalation ongoing with intermittent oral administration schedule in patients with...
December 04, 2013 07:00 ET | Source: Curis, Inc.

Curis to Present at the Oppenheimer 24th Annual Healthcare Conference

LEXINGTON, Mass., Dec. 4, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human cancers,...
November 26, 2013 07:00 ET | Source: Curis, Inc.

Curis to Present at Upcoming Investor Conferences

LEXINGTON, Mass., Nov. 26, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human cancers,...
November 06, 2013 06:00 ET | Source: Curis, Inc.

Curis Reports Third Quarter 2013 Financial Results and Provides CUDC-427 Development Update

-- CUDC-427 Phase 1 Trial Placed on Partial Clinical Hold by FDA -- -- Company to Host Conference Call Today at 8:30 a.m. EST -- LEXINGTON, Mass., Nov. 6, 2013 (GLOBE NEWSWIRE) -- Curis, Inc....